Cargando…
Phosphate and fibroblast growth factor 23 in diabetes
Diabetes is associated with a strongly elevated risk of cardiovascular disease, which is even more pronounced in patients with diabetic nephropathy. Currently available guideline-based efforts to correct traditional risk factors are only partly able to attenuate this risk, underlining the urge to id...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302806/ https://www.ncbi.nlm.nih.gov/pubmed/34283205 http://dx.doi.org/10.1042/CS20201290 |
_version_ | 1783726948429594624 |
---|---|
author | van der Vaart, Amarens Yeung, Stanley M.H. van Dijk, Peter R. Bakker, Stephan J.L. de Borst, Martin H. |
author_facet | van der Vaart, Amarens Yeung, Stanley M.H. van Dijk, Peter R. Bakker, Stephan J.L. de Borst, Martin H. |
author_sort | van der Vaart, Amarens |
collection | PubMed |
description | Diabetes is associated with a strongly elevated risk of cardiovascular disease, which is even more pronounced in patients with diabetic nephropathy. Currently available guideline-based efforts to correct traditional risk factors are only partly able to attenuate this risk, underlining the urge to identify novel treatment targets. Emerging data point towards a role for disturbances in phosphate metabolism in diabetes. In this review, we discuss the role of phosphate and the phosphate-regulating hormone fibroblast growth factor 23 (FGF23) in diabetes. We address deregulations of phosphate metabolism in patients with diabetes, including diabetic ketoacidosis. Moreover, we discuss potential adverse consequences of these deregulations, including the role of deregulated phosphate and glucose as drivers of vascular calcification propensity. Finally, we highlight potential treatment options to correct abnormalities in phosphate and FGF23. While further studies are needed to more precisely assess their clinical impact, deregulations in phosphate and FGF23 are promising potential target in diabetes and diabetic nephropathy. |
format | Online Article Text |
id | pubmed-8302806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83028062021-08-05 Phosphate and fibroblast growth factor 23 in diabetes van der Vaart, Amarens Yeung, Stanley M.H. van Dijk, Peter R. Bakker, Stephan J.L. de Borst, Martin H. Clin Sci (Lond) Cardiovascular System & Vascular Biology Diabetes is associated with a strongly elevated risk of cardiovascular disease, which is even more pronounced in patients with diabetic nephropathy. Currently available guideline-based efforts to correct traditional risk factors are only partly able to attenuate this risk, underlining the urge to identify novel treatment targets. Emerging data point towards a role for disturbances in phosphate metabolism in diabetes. In this review, we discuss the role of phosphate and the phosphate-regulating hormone fibroblast growth factor 23 (FGF23) in diabetes. We address deregulations of phosphate metabolism in patients with diabetes, including diabetic ketoacidosis. Moreover, we discuss potential adverse consequences of these deregulations, including the role of deregulated phosphate and glucose as drivers of vascular calcification propensity. Finally, we highlight potential treatment options to correct abnormalities in phosphate and FGF23. While further studies are needed to more precisely assess their clinical impact, deregulations in phosphate and FGF23 are promising potential target in diabetes and diabetic nephropathy. Portland Press Ltd. 2021-07 2021-07-20 /pmc/articles/PMC8302806/ /pubmed/34283205 http://dx.doi.org/10.1042/CS20201290 Text en © 2021 The Author(s). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . Open access for this article was enabled by the participation of University of Groningen in an all-inclusive Read & Publish pilot with Portland Press and the Biochemical Society. |
spellingShingle | Cardiovascular System & Vascular Biology van der Vaart, Amarens Yeung, Stanley M.H. van Dijk, Peter R. Bakker, Stephan J.L. de Borst, Martin H. Phosphate and fibroblast growth factor 23 in diabetes |
title | Phosphate and fibroblast growth factor 23 in diabetes |
title_full | Phosphate and fibroblast growth factor 23 in diabetes |
title_fullStr | Phosphate and fibroblast growth factor 23 in diabetes |
title_full_unstemmed | Phosphate and fibroblast growth factor 23 in diabetes |
title_short | Phosphate and fibroblast growth factor 23 in diabetes |
title_sort | phosphate and fibroblast growth factor 23 in diabetes |
topic | Cardiovascular System & Vascular Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302806/ https://www.ncbi.nlm.nih.gov/pubmed/34283205 http://dx.doi.org/10.1042/CS20201290 |
work_keys_str_mv | AT vandervaartamarens phosphateandfibroblastgrowthfactor23indiabetes AT yeungstanleymh phosphateandfibroblastgrowthfactor23indiabetes AT vandijkpeterr phosphateandfibroblastgrowthfactor23indiabetes AT bakkerstephanjl phosphateandfibroblastgrowthfactor23indiabetes AT deborstmartinh phosphateandfibroblastgrowthfactor23indiabetes |